Meng Li

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 17

Top Venues

PharmacoEconomics

The oncologist

Future oncology (London, England)

JCO oncology practice

University of Southern California

University of Washington (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Southern California Sep 05 2018

United States

Postdoctoral Scholar :: Schaeffer Center of Health Economics & Policy

Education History

University of Washington Sep 15 2013

United States

PHD :: Pharmacy

Publications

Meng Li, Louis P Garrison
Incorporating Real Option Value in Valuing Innovation: A Way Forward. PharmacoEconomics 42 (Suppl 2) (2024)
Aryana Sepassi, Meng Li, Jason A Zell, Alexandre Chan, Ila M Saunders, Dana B Mukamel
Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis. The oncologist 29 (4) (2024)
Meng Li, Louis P Garrison
Incorporating Real Option Value in Valuing Innovation: A Way Forward. PharmacoEconomics (2024)
William Bruce Wong, Stacey Kowal, Tu My To, Achal Patel, David L Veenstra, Louis P Garrison, Meng Li
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future oncology (London, England) (2024)
Aryana Sepassi, Meng Li, Jason A Zell, Alexandre Chan, Ila M Saunders, Dana B Mukamel
Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis. The oncologist 29 (4) (2024)
Meng Li, Louis P Garrison
Incorporating Real Option Value in Valuing Innovation: A Way Forward. PharmacoEconomics 42 (Suppl 2) (2024)
Aryana Sepassi, Meng Li, Jason A Zell, Alexandre Chan, Ila M Saunders, Dana B Mukamel
Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis. The oncologist 29 (4) (2024)
Meng Li, Louis P Garrison
Incorporating Real Option Value in Valuing Innovation: A Way Forward. PharmacoEconomics 42 (Suppl 2) (2024)
Aryana Sepassi, Meng Li, Jason A Zell, Alexandre Chan, Ila M Saunders, Dana B Mukamel
Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis. The oncologist 29 (4) (2024)
William Bruce Wong, Stacey Kowal, Tu My To, Achal Patel, David L Veenstra, Louis P Garrison, Meng Li
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future oncology (London, England) (2024)
Aryana Sepassi, Meng Li, Jason Zell, Alexandre Chan, Ila M Saunders, Dana B Mukamel
Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis. The oncologist (2024)
William Bruce Wong, Stacey Kowal, Tu My To, Achal Patel, David L Veenstra, Louis P Garrison, Meng Li
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future oncology (London, England) 20 (16) (2024)
Jingyan Yang, Basit I Chaudhry, Andrew T Yue, Joshua A Roth, John M Kelton, Ahmed Shelbaya, Lisa Tran, Meng Li
The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study. Advances in therapy (2023)
Woojung Lee, William Bruce Wong, Stacey Kowal, Louis P Garrison, David L Veenstra, Meng Li
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. PharmacoEconomics 40 (6) (2022)
Meng Li, Kaiping Liao, I-Wen Pan, Ya Chen Tina Shih
Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer. JCO oncology practice 18 (11) (2022)
Meng Li, Anirban Basu, Caroline S Bennette, David L Veenstra, Louis P Garrison
Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health economics 28 (7) (2020)
Meng Li, Mark Bounthavong
Medicare Beneficiaries, Especially Unsubsidized Minorities, Struggle to Pay for Prescription Drugs: Results from the Medicare Current Beneficiary Survey. Journal of general internal medicine 35 (4) (2019)

Meng Li.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Meng Li